Articles Tagged With:
-
New Tool Helps With Study Recruitment
Department of Energy researchers developed a new tool to connect cancer patients with clinical trials. The tool uses a Netflix-style of analytics to recommend studies that would be a good fit for particular patients.
-
Next Challenge for IRBs: Nanomedicine Research Risks
IRB members soon will see — if they haven’t already — protocols involving medical therapies with materials that are so tiny that a human hair is 80,000 times their width.
-
Diverse Populations Joining NIH All of Us
Nearly a quarter of a million people have joined the National Institutes of Health’s ambitious All of Us precision medicine initiative — with a large response from racial and ethnic minorities who have been historically victimized or ignored by human research.
-
Infectious Disease Alert Updates
California Inmates With Cocci Lose Appeal; Tuberculosis Testing in Small Children
-
Omadacycline (Nuzyra)
Omadacycline was approved in 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
-
Histoplasmosis — Expansion of Risk Areas and Need for More Standardized Practice
Histoplasmosis is increasingly seen beyond the previous risk areas of the Ohio and Mississippi River valleys. Diagnostic and treatment practices vary widely.
-
Should IRBs Set an Incentive Pay Limit?
Not all IRBs and research institutions specifically address limits to how much researchers can compensate study participants. But allowing these limits to default to what is reportable to the IRS as income could be a mistake, one IRB chair says.
-
Vancomycin for MRSA Pneumonia Following Influenza in Children
Coinfection with methicillin-resistant Staphylococcus aureus (MRSA) in children with influenza is associated with high fatality. Data support the addition of a second anti-MRSA antibiotic to vancomycin in severely ill children.
-
Is Fecal Microbiota Transplantation Superior to Fidaxomicin for Recurrent Clostridioides difficile Infection?
In a randomized clinical trial, researchers found the combination of oral vancomycin followed by fecal microbiota transplantation was superior to treatment with fidaxomicin or vancomycin alone for patients with recurrent Clostridioides difficile infection.
-
Electronic Informed Consent Platform Enhances Education and Engagement
Since Memorial Sloan Kettering Cancer Center implemented the electronic informed consent process, thousands of research participants have consented electronically, increasing at a rate of about 500 per month.